|
Acute onset pain
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Influence of CYP2D6 activity on pre-emptive analgesia by the N-methyl-D-aspartate antagonist dextromethorphan in a randomized controlled trial of acute pain.
|
23340533 |
2013 |
|
Addictive Behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The CYP2D6 gene determines oxycodone's phenotype-specific addictive potential: implications for addiction prevention and treatment.
|
24495562 |
2014 |
|
Adenocarcinoma
|
0.030 |
GeneticVariation
|
group |
BEFREE |
According to histological type, adenocarcinoma and small cell carcinoma were not associated with the presence of the CYP2D6*9 mutant allele and a non-significant higher occurrence of the mutant allele was observed for squamous cell carcinoma (OR 1.74, 95% CI 0.6-4.8).
|
8895499 |
1996 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
BEFREE |
In this context, the suggestion of a positive relationship between CYP2D6 and adenocarcinoma seems to us to merit investigation.
|
7586196 |
1995 |
|
Adenocarcinoma
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Relative to subjects with an inactivating allele, those with an additional copy of the CYP2D6 gene and no inactivating alleles may be at increased risk of lung cancer, particularly for adenocarcinoma (OR = 3.61, 95% CI 1.08-11.7 for African-Americans and OR = 2.20, 95% CI 0.69-6.0 for Caucasians).
|
9214604 |
1997 |
|
Adenoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The data indicate the GSTM1 null and CYP2D6 EM genotypes are not associated with altered expression of p53 or, mutation of gsp and ras in these adenomas and, suggest the CYP2D6 PM genotype is associated with a reduced risk of pituitary adenomas and, that GSTM1*B confers greater protection than GSTM1*A.
|
7614700 |
1995 |
|
Adenoma of large intestine
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
P450 CYP2C9*3 heterozygotes had reduced CRA risk compared with homozygotes for the reference allele [odds ratio (OR): 0.60; 95% confidence interval (CI): 0.36-0.99], whereas CYP2D6*4 homozygotes (OR: 2.72; 95% CI: 1.18-6.27) and GSTM1 'null' individuals (OR: 1.43; 95% CI: 1.04-1.98) were at increased risk.
|
20375710 |
2010 |
|
Adult Acute Lymphocytic Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
The genetic polymorphisms of biotransformation phase I enzymes, cytochrome P450 (CYP1A1 and CYP2D6), and phase II enzymes, glutathione S-transferase (GSTM1 and GSTT1), were analyzed in 204 healthy persons and 348 leukemia patients, who suffered from also acute lymphoblastic leukemia (ALL), acute nonlymphoblastic leukemia (ANLL) chronic myelogenous leukemia (CML), from the Han ethnic group in Changsha City of Hunan Province of China.
|
18414197 |
2008 |
|
Adult Acute Lymphocytic Leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The NAT2 slow-acetylator, CYP1A1*2A and GSTM1 null genotypes were shown to be significant risk determinants of ALL (OR=1.6, 1.8 and 1.8, respectively), whereas, polymorphisms in CYP2D6 and GSTT1 genes did not seem to play an important role in the aetiology of ALL.
|
10953966 |
2000 |
|
Adult Liver Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 genes and risk of liver cancer.
|
7898230 |
1995 |
|
Adult Meningioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Logistic regression analysis showed GSTT1 null and CYP2D6 poor metabolizer were risk factors in astrocytoma (odds ratio = 2.67 P = 0.0005 and odds ratio = 4.17 P = 0.0043, respectively) and meningioma (odds ratio = 4.52, P = 0.0001 and odds ratio = 4.90, P = 0.0132, respectively) when corrected for the other variables.
|
7671227 |
1995 |
|
Advanced breast cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.
|
23686417 |
2013 |
|
Adverse reaction to drug
|
0.300 |
Biomarker
|
group |
CTD_human |
Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
|
23609392 |
2013 |
|
Afterbirth pain
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events.
|
28696420 |
2018 |
|
Afterbirth pain
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
|
21743374 |
2011 |
|
Agnosia for Pain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Influence of CYP2D6 activity on pre-emptive analgesia by the N-methyl-D-aspartate antagonist dextromethorphan in a randomized controlled trial of acute pain.
|
23340533 |
2013 |
|
Agnosia for Pain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibiting the induced brain CYP2D reversed the change in oxycodone levels (1.2-fold; P > 0.1) and analgesia (1.1-fold; P > 0.3).
|
29266563 |
2019 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of CYP2D6 Polymorphisms on Postoperative Fentanyl Analgesia in Gastric Cancer Patients.
|
25825958 |
2015 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study indicates that the CYP2D6*10 allele has significant impact on analgesia with tramadol in a Chinese population.
|
16960721 |
2006 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim was to study the relationship between CYP2D6 genotype and codeine analgesia among women recovering from c-section.
|
21743374 |
2011 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 and CYP3A genotypes did not affect analgesic concentration or duration of analgesia.
|
28643329 |
2018 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, CYP2D6 genotype has an impact on analgesia with tramadol.
|
14499440 |
2003 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is unclear whether these other pro-drugs may be as completely dependent on CYP2D6 for their analgesia as codeine.
|
16631290 |
2006 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
The case we present, as well as the literature we review, demonstrates the clinical utility of CYP2D6 genotyping in patients with adverse effects from analgesia therapy.
|
17986163 |
2007 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we would recommend CYP2D6 genotyping to anticipate the needs for analgesia, which will help to adjust opioid dose and maximize clinical efficacy while reducing side effects.
|
29546421 |
2019 |